DPBIO
DPBIO is a San Diego-based biotechnology company that develops the CytoSpark® droplet microfluidics platform for ultra-high-throughput, single-cell antibody discovery and enzyme screening, serving pharmaceutical and biotech companies plus academic research institutions.
- Company typePrivate
- Founded2017
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
DPBIO firmographics
Firmographics- Name
- DPBIO
- Legal name
- DPBIO, Inc.
- Website
- https://dp-bio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- DPBIO is a San Diego-based biotechnology company that develops the CytoSpark® droplet microfluidics platform for ultra-high-throughput, single-cell antibody discovery and enzyme screening, serving pharmaceutical and biotech companies plus academic research institutions.
- Ownership category
- akta.pro rank
DPBIO industry classification
Industry- Product category
- Life Sciences Microfluidics Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where DPBIO is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
DPBIO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- CytoSpark Platform: The company generates revenue through the sale of its CytoSpark droplet microfluidics platform, which provides single-cell analysis capabilities. Given the nature of scientific instruments in the biotech space, this likely involves hardware sales combined with consumables and potentially service/support subscriptions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
DPBIO product offering
Product offeringCore offering
DPBIO develops and sells the CytoSpark® platform, an ultra-high-throughput droplet microfluidics system that delivers single-cell resolution for antibody discovery, enzyme screening, and related life science applications. The platform is targeted at pharmaceutical and biotechnology customers needing massively parallel single-cell analysis capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- CytoSpark®: Ultra-high-throughput, single-cell resolution platform for antibody discovery, enzyme screening, and beyond.
Products and services
- CytoSpark® Platform Ultra-high-throughput, single-cell resolution droplet microfluidics platform for antibody discovery, enzyme screening, and related life science research, intended for pharmaceutical, biotechnology, and academic research customers.
Companies that use DPBIO
Customer profileSegments2 records
Ideal customer profiles2 records
DPBIO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
DPBIO partnerships and signals
Strategic signalScale indicators1 record
DPBIO competitors and assessment
Company assessmentDirect peers
- Berkeley Lights (now PhenomeX): PhenomeX (formerly Berkeley Lights) offers the Beacon optofluidic platform for single-cell functional screening in antibody discovery. It competes head-to-head with DPBIO's CytoSpark® in antibody discovery and enzyme screening applications.
- Standard BioTools (formerly Fluidigm): Standard BioTools produces mass cytometry and microfluidic single-cell analysis instruments used in pharma and academic research. It competes with DPBIO in single-cell workflows and shares the microfluidic platform heritage and pharma/biotech customer base.
- 10x Genomics: 10x Genomics is a leading single-cell analysis platform company offering Chromium droplet-based systems for antibody discovery, immune profiling, and genomics. It directly competes with DPBIO's CytoSpark® in single-cell resolution screening for pharma and academic customers.
- Sphere Fluidics: Sphere Fluidics develops picodroplet microfluidic instruments and consumables for single-cell analysis and antibody discovery. It is a focused, smaller-scale droplet microfluidics peer comparable to DPBIO in technology category and target applications.
- Cytena (a Sartorius company): Cytena specializes in droplet-based single-cell printing and analysis platforms used in cell line development and antibody discovery. Its core droplet microfluidics technology and pharma/biotech customer base overlap directly with CytoSpark®.
Broad incumbents
- Bio-Techne: Bio-Techne is a diversified life-science tools provider with reagents, antibodies, and assay platforms serving pharma and academic customers. It is comparable to DPBIO as a horizontal life-science tools peer serving similar buyer segments.
- Sartorius: Sartorius (parent of Cytena) is a bioprocessing and lab tools incumbent with growing presence in cell and gene therapy workflows. It overlaps with DPBIO at the customer level (pharma/biotech) and increasingly in single-cell and cell-line development tools.
- Becton, Dickinson and Company (BD): BD is a large life sciences and diagnostics incumbent offering flow cytometry and single-cell analysis instruments (BD FACSDiscover™, BD CellView™). It competes with DPBIO in pharma and academic customer workflows with a much broader portfolio and global reach.
- Bruker: Bruker offers advanced analytical instruments, mass cytometry, and proteomics tools used in pharma and academic research. It is comparable as a broader life-science instrument incumbent with adjacent single-cell and proteomics capabilities relevant to DPBIO's customer base.
Emerging players
- Mission Bio: Mission Bio provides single-cell multi-omics platforms (Tapestri) for genomics and targeted antibody repertoire profiling, overlapping with DPBIO's single-cell resolution focus in translational and pharma research.
Market position
Customer concentration
DPBIO social profiles
Digital presenceDPBIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
DPBIO leadership team
Management profileNumber of profiles
Profiles1 record
DPBIO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DPBIO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DPBIO
What does DPBIO do?
DPBIO develops and sells the CytoSpark® platform, an ultra-high-throughput droplet microfluidics system that delivers single-cell resolution for antibody discovery, enzyme screening, and related life science applications. The platform is targeted at pharmaceutical and biotechnology customers needing massively parallel single-cell analysis capabilities.
Is DPBIO a public or private company?
DPBIO is a private company. It is classified as unknown and is currently operating.
When was DPBIO founded?
DPBIO was founded in 2017. It employs 51 to 100 people.
Where is DPBIO based?
DPBIO is headquartered in San Diego, United States, in the North America region.
How does DPBIO make money?
One revenue line is on record: cytoSpark Platform.
Who are DPBIO's main competitors?
Direct peers on record are Berkeley Lights (now PhenomeX), Standard BioTools (formerly Fluidigm), 10x Genomics, Sphere Fluidics and Cytena (a Sartorius company). Broad incumbents are Bio-Techne, Sartorius, Becton, Dickinson and Company (BD) and Bruker. Mission Bio is listed as an emerging player.
Does DPBIO have an API?
No public API is recorded for DPBIO.
What industry is DPBIO in?
DPBIO's product category is Life Sciences Microfluidics Instrumentation. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 334516 and its SIC code is 3841.